Triple GIP / GLP-1 / glucagon receptor agonist
Retatrutide
Human clinical trialsAn investigational "triple agonist" currently in late-stage clinical trials.
Evidence
Human clinical trials
Regulatory status
Investigational. Not FDA-approved.
Class
Triple GIP / GLP-1 / glucagon receptor agonist
What it is
Retatrutide is designed to activate three hormone receptors at once: GIP, GLP-1, and glucagon. Adding glucagon activity is being studied for its effect on energy expenditure and liver fat.
What the research shows
- A phase 2 trial published in the New England Journal of Medicine (2023) reported substantial weight reduction over 48 weeks.
- Phase 3 trials are ongoing. Long-term safety data is not yet available.
Read the published research on PubMed →
Researched for
Retatrutide is not FDA-approved for the uses people commonly discuss. Its safety and effectiveness in people have not been established. Talk to a licensed provider before making any decision.
Educational content, not medical advice. This page does not recommend or dose any substance.
Related peptides
GLP-1 receptor agonist
Semaglutide
A GLP-1 receptor agonist and one of the most studied peptide medicines in the world.
FDA-approved drugDual GIP / GLP-1 receptor agonistTirzepatide
The first approved medicine that activates both the GIP and GLP-1 receptors.
FDA-approved drugLong-acting amylin analogCagrilintide
An amylin analog being studied alone and in combination with semaglutide.
Human clinical trials